Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease (EXPEDITION EXT)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT01127633
First received: May 19, 2010
Last updated: September 28, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: August 2020
  Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: September 29, 2014